Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

NCT06173505 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Nonsquamous Non-small Cell Lung Cancer

Interventions

COMBINATION_PRODUCT: Vudalimab + Carboplatin + Pemetrexed
COMBINATION_PRODUCT: Pembrolizumab + Carboplatin + Pemetrexed

Sponsor

Xencor, Inc.